MARKET

BPMC

BPMC

Blueprint Medicines Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.94
+0.61
+1.10%
Closed 16:00 05/25 EDT
OPEN
55.00
PREV CLOSE
55.33
HIGH
56.07
LOW
53.97
VOLUME
388.77K
TURNOVER
--
52 WEEK HIGH
117.86
52 WEEK LOW
50.96
MARKET CAP
3.33B
P/E (TTM)
-5.0646
1D
5D
1M
3M
1Y
5Y
What 3 Analyst Ratings Have To Say About Blueprint Medicines
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Benzinga · 6d ago
--Piper Sandler Adjusts Price Target on Blueprint Medicines to $65 From $84, Maintains Neutral Rating
MT Newswires · 05/19 08:15
Insider Sell: Blueprint Medicines
MT Newswires · 05/18 17:36
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on May 1, 2022, the Compensation Committee of Blueprint Medicines' B...
PR Newswire · 05/05 20:01
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Zacks · 05/04 17:22
--Baird Adjusts Price Target on Blueprint Medicines to $96 From $123, Keeps Outperform Rating
MT Newswires · 05/04 10:15
--Wedbush Raises Price Target for Blueprint Medicines to $129 From $126, Maintains Outperform Rating
MT Newswires · 05/03 16:06
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 05/03 13:01
More
No Data
Learn about the latest financial forecast of BPMC. Analyze the recent business situations of Blueprint Medicines Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
26.67%Buy
40.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BPMC stock price target is 102.57 with a high estimate of 152.00 and a low estimate of 65.00.
High152.00
Average102.57
Low65.00
Current 55.94
EPS
Actual
Estimate
-4.32-3.24-2.16-1.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 389
Institutional Holdings: 64.85M
% Owned: 108.86%
Shares Outstanding: 59.57M
TypeInstitutionsShares
Increased
98
4.11M
New
29
421.71K
Decreased
108
3.74M
Sold Out
33
999.11K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.02%
Key Executives
Chairman/Executive Director
Jeffrey Albers
President/Chief Executive Officer/Director
Kathryn Haviland
Chief Financial Officer
Michael Landsittel
Corporate Executive
Fouad Namouni
Chief Operating Officer
Christina Rossi
Chief Human Resource Officer
Debra Durso-Bumpus
Executive Vice President
Anthony Boral
Senior Vice President
Christopher Murray
Chief Scientific Officer
Percy Carter
Chief Compliance Officer
Tracey McCain
Vice President/Controller
Ariel Hurley
Other
Becker Hewes
Other
Helen Ho
Other
Philina Lee
Lead Director/Independent Director
Lynn Seely
Director
Daniella Beckman
Independent Director
Alexis Borisy
Independent Director
Lonnel Coats
Independent Director
George Demetri
Independent Director
Mark Goldberg
Independent Director
Nicholas Lydon
Independent Director
Charles Rowland
No Data
No Data
About BPMC
Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company is focused on crafting drug candidates that provide clinical responses to patients without adequate treatment options. Its lead medicines are AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib). Avapritinib is used for the treatment of systemic mastocytosis (SM), a rare hematologic disorder that causes an overproduction of mast cells and the accumulation of mast cells in the bone marrow and other organs. It is also commercializing avapritinib for the treatment of patients with PDGFRA exon 18 mutant gastrointestinal stromal tumors (GIST). The Company is developing and commercializing pralsetinib for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), and for the treatment of RET-altered thyroid carcinoma, including medullary thyroid carcinoma (MTC).

Webull offers kinds of Blueprint Medicines Corp stock information, including NASDAQ:BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.